About PGxl
PGXL is an internationally recognized pioneer in the application of molecular diagnostics to pharmacogenetics and is the first laboratory to be CLIA-certified specifically for pharmacogenetics testing. The company was founded in 2005 by Dr. Roland Valdes, Jr., and Dr. Mark W. Linder, researchers who are among the worldwide thought leaders in the science underlying personalized medicine. Our scientists are leading the way in the incorporation of genetic information into the practice of medicine.
News
-
PerMIT Makes Its Commercial Debut
ARUP Laboratories, a national clinical and anatomic pathology reference laboratory, is the first site to deploy PGXL’s PerMIT software to ...
-
PGXL in Joint Venture to Commercialize Sleep Apnea Diagnostic
PGXL/Laboratories and its sister company, PGXL/Technologies, have entered into a joint venture with Appian Partners LLC of Severna Park, Maryland, ...
-
Equity Investment in PGXL
The University of Louisville Foundation has made a "substantial" equity investment in PGXL, helping to fund the expansion of the ...
-
Contract Research Portfolio Grows
PGXL will provide laboratory services for SK Life Science, which manages global clinical trials of new drugs. The contract will ...
PGxl Blog
-
And the Winner Is…
The National Association of Clinical Biochemistry has given a Distinguished Abstract Award to PGXL's Assistant Lab Director, Dr. Mark Borgman. Borgman's The SLC6A4 Long ...
-
The Value of 2C9/Warfarin Testing Goes Beyond Initial Dosing
A study by pharmacy benefits management company Prime Therapeutics is being touted as evidence that genetic testing for warfarin is being ...
-
Adverse Drug Reactions by Drug Class
Cases Blog digs into the research and identifies the four classes of drugs responsible for 67% of adverse drug reactions: warfarin, ...
-
Mobile or Digital Health: It’s All Personalized Medicine to Us
There's an interesting semantic discussion going on, captured at MedCityNews: If you listen to people discuss mobile health and digital health, ...